Want to see KOD full AI Analyst Report?
KOD Stock Chart & Stats
$41.41
$0.50(1.21%)
At close: 4:00 PM EDT
$41.41
$0.50(1.21%)
Day’s Range― - ―
52-Week Range$8.29 - $47.84
Previous Close$42.01
Volume464.83K
Average Volume (3M)751.22K
Market Cap
$2.41B
Enterprise Value$2.47K
Total Cash (Recent Filing)$125.90M
Total Debt (Recent Filing)$95.70M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.19
Shares Outstanding62,849,457
10 Day Avg. Volume539,931
30 Day Avg. Volume751,223
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.45
Price to Sales (P/S)0.00
P/FCF Ratio-10.90
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.25Price Target Upside74.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical PipelineA late-stage portfolio and multiple upcoming pivotal readouts provide several potential paths toward regulatory approval and commercialization. Successful execution could transition Kodiak from a pre-revenue biotech into a revenue-generating ophthalmology company.
Cash RunwayExpected funding into 2027 gives the company time to complete important Phase 3 studies and regulatory preparations without an immediately required financing event. This supports operational continuity while key clinical catalysts mature.
Lower Debt BurdenMaterial debt reduction lowers interest and repayment pressure compared with the prior year, improving the capital structure. Although equity has also declined, reduced leverage gives Kodiak somewhat greater financial flexibility as it advances its pipeline.
Bears Say
No Revenue And Persistent LossesKodiak remains dependent on clinical development rather than recurring product sales, leaving commercialization and profitability unproven. Large ongoing operating losses could persist for several periods if trials, approvals, or launches are delayed.
Heavy Cash ConsumptionSustained negative cash generation requires Kodiak to fund operations through existing reserves, partnerships, or future capital raises. Continued trial and regulatory spending could shorten the runway or create dilution risk before products generate revenue.
Shrinking Equity BaseThe sharp contraction in equity indicates a thinner financial cushion after years of losses. This weakens resilience if development costs rise or milestones slip, and may increase reliance on external financing despite the reduction in debt.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences’s price range in the past 12 months?
Kodiak Sciences lowest stock price was $8.29 and its highest was $47.84 in the past 12 months.
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $2.41B.
When is Kodiak Sciences’s upcoming earnings report date?
Kodiak Sciences’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.
How were Kodiak Sciences’s earnings last quarter?
Kodiak Sciences released its earnings results on Aug 13, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.956 by -$0.094.
Is Kodiak Sciences overvalued?
According to Wall Street analysts Kodiak Sciences’s price is currently Undervalued.
Does Kodiak Sciences pay dividends?
Kodiak Sciences does not currently pay dividends.
What is Kodiak Sciences’s EPS estimate?
Kodiak Sciences’s EPS estimate is -1.
How many shares outstanding does Kodiak Sciences have?
Kodiak Sciences has 62,849,457 shares outstanding.
What happened to Kodiak Sciences’s price movement after its last earnings report?
Kodiak Sciences reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.956. Following the earnings report the stock price went up 3.427%.
Which hedge fund is a major shareholder of Kodiak Sciences?
Currently, no hedge funds are holding shares in KOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.25 (74.47% Upside)
$72.25 (74.47% Upside)
Blogger Sentiment
Bullish
KOD Sentiment 67%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.7%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
401.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Kodiak Sciences
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
KOD Stock 12 Month Forecast
Average Price Target
$72.25
▲(74.47% Upside)
Technical Analysis
Urogen Pharma
―
Nurix Therapeutics
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
33.51% Insiders
10.78% Mutual Funds
6.92% Other Institutional Investors
37.94% Public Companies and
Individual Investors